19 A second report of the same trial, showed a trend in favor of thalidomide and a significant benefit in the subgroup of patients with karyotypic abnormalities. 13 In the Dutch (Lokhorst et al. , 2008) and British ) and British (Morgan et al. , 2008) studies, the PFS benefit did not translate into a significant OS benefit, again because of a shorter OS after relapse in the thalidomide group. 16 , 17 How can we analyze these differences?
1
—
—